Market Overview

Dan Nathan Sees Unusual Options Activity In Pfizer

Related PFE
The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial
The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
FDA creates new accelerated review pathway for generic drug applications (Seeking Alpha)

On CNBC's "Options Action", Dan Nathan spoke about unusually high options activity in Pfizer Inc. (NYSE: PFE) on Tuesday. The call options volume was two times that of puts on a day when the stock dropped 1.65 percent.

During the trading session, there was a purchase of 1,000 contracts of the December 44 calls for $0.30. The trade breaks even at $44.30 or 4.48 percent above the current stock price.

Posted-In: CNBC Dan Nathan Options ActionMedia


Related Articles (PFE)

View Comments and Join the Discussion!

Altria, Lowe's, Target, XLU: 'Fast Money' Picks For December 19

Tim Biggam's ProShares Ultra VIX Short-Term Futures Trade